Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Shanghai Kechow Pharma.

    Client Virtual Booth

    SHANGHAI KECHOW PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Shanghai Kechow Pharma
    China Flag
    Country
    Country
    China
    Address
    Address
    Room 3M, No.780 Cailun Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, PRC.
    Telephone
    Telephone
    +86-21-51323990
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://en.kechowpharma.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previo...

    Details:

    HL-085 (tunlametinib) is a small molecule inhibitor of Mitogen-activated protein kinase. It is approved by NMPA for the treatment of NRAS Mutated Advanced Melanoma.


    Lead Product(s): Tunlametinib

    Therapeutic Area: Oncology Product Name: HL-085

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 18, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Roche and KeChow Reach a Cooperation Agreement

    Details:

    Under this collaboration, KeChow will promote Roche's Zelboraf® in China. Zelboraf® is an oral small molecule, selective BRAF inhibitor indicated for the treatment of patients with BRAF V600 mutation-positive advanced or inoperable melanoma.


    Lead Product(s): Vemurafenib

    Therapeutic Area: Oncology Product Name: Zelboraf

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration August 20, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search